1
|
An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect. Neoplasia 2018; 21:159-171. [PMID: 30591421 PMCID: PMC6314220 DOI: 10.1016/j.neo.2018.11.009] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2018] [Revised: 11/21/2018] [Accepted: 11/26/2018] [Indexed: 12/21/2022] Open
Abstract
Tumor hypoxia contributes to resistance to anticancer therapies. Hypoxia-activated prodrugs (HAPs) selectively target hypoxic cells and their activity can extend to well-oxygenated areas of tumors via diffusion of active metabolites. This type of bystander effect has been suggested to be responsible for the single agent activity of the clinical-stage HAP evofosfamide (TH-302) but direct evidence is lacking. To dissect the contribution of bystander effects to TH-302 activity, we implemented a Green's function pharmacokinetic (PK) model to simulate the spatial distribution of O2, TH-302 and its cytotoxic metabolites, bromo-isophosphoramide mustard (Br-IPM) and its dichloro derivative isophosphoramide mustard (IPM), in two digitized tumor microvascular networks. The model was parameterized from literature and experimentally, including measurement of diffusion coefficients of TH-302 and its metabolites in multicellular layer cultures. The latter studies demonstrate that Br-IPM and IPM cannot diffuse significantly from the cells in which they are generated, although evidence was obtained for diffusion of the hydroxylamine metabolite of TH-302. The spatially resolved PK model was linked to a pharmacodynamic (PD) model that describes cell killing probability at each point in the tumor microregion as a function of Br-IPM and IPM exposure. The resulting PK/PD model accurately predicted previously reported monotherapy activity of TH-302 in H460 tumors, without invoking a bystander effect, demonstrating that the notable single agent activity of TH-302 in tumors can be accounted for by significant bioreductive activation of TH-302 even in oxic regions, driven by the high plasma concentrations achievable with this well-tolerated prodrug.
Collapse
|
2
|
Skarbek C, Lesueur LL, Chapuis H, Deroussent A, Pioche−Durieu C, Daville A, Caron J, Rivard M, Martens T, Bertrand JR, Le Cam E, Vassal G, Couvreur P, Desmaele D, Paci A. Preactivated Oxazaphosphorines Designed for Isophosphoramide Mustard Delivery as Bulk Form or Nanoassemblies: Synthesis and Proof of Concept. J Med Chem 2014; 58:705-17. [DOI: 10.1021/jm501224x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Charles Skarbek
- Université
Paris-Sud, Centre National de la Recherche
Scientifique (CNRS), and Gustave Roussy Cancer
Campus Grand Paris, Laboratoire de Vectorologie et Thérapeutiques Anticancéreuses, UMR 8203, Villejuif, France-94805
| | - Lea L. Lesueur
- Université
Paris-Sud, Centre National de la Recherche
Scientifique (CNRS), and Gustave Roussy Cancer
Campus Grand Paris, Laboratoire de Vectorologie et Thérapeutiques Anticancéreuses, UMR 8203, Villejuif, France-94805
| | - Hubert Chapuis
- Université Paris-Sud, Institut Galien, UMR 8612, Châtenay-Malabry, France-92296
| | - Alain Deroussent
- Université
Paris-Sud, Centre National de la Recherche
Scientifique (CNRS), and Gustave Roussy Cancer
Campus Grand Paris, Laboratoire de Vectorologie et Thérapeutiques Anticancéreuses, UMR 8203, Villejuif, France-94805
| | | | - Aurore Daville
- Université
Paris-Sud, Centre National de la Recherche
Scientifique (CNRS), and Gustave Roussy Cancer
Campus Grand Paris, Laboratoire de Vectorologie et Thérapeutiques Anticancéreuses, UMR 8203, Villejuif, France-94805
| | - Joachim Caron
- Université Paris-Sud, Institut Galien, UMR 8612, Châtenay-Malabry, France-92296
| | - Michael Rivard
- Université Paris Est Créteil, Institut de Chimie et des Matériaux Paris-Est (ICMPE), UMR 7182, Thiais, France-94320
| | - Thierry Martens
- Université Paris Est Créteil, Institut de Chimie et des Matériaux Paris-Est (ICMPE), UMR 7182, Thiais, France-94320
| | - Jean-Rémi Bertrand
- Université
Paris-Sud, Centre National de la Recherche
Scientifique (CNRS), and Gustave Roussy Cancer
Campus Grand Paris, Laboratoire de Vectorologie et Thérapeutiques Anticancéreuses, UMR 8203, Villejuif, France-94805
| | - Eric Le Cam
- CNRS UMR8126, Université Paris Sud 11, Institut Gustave Roussy, Villejuif, France-94805
| | - Gilles Vassal
- Université
Paris-Sud, Centre National de la Recherche
Scientifique (CNRS), and Gustave Roussy Cancer
Campus Grand Paris, Laboratoire de Vectorologie et Thérapeutiques Anticancéreuses, UMR 8203, Villejuif, France-94805
| | - Patrick Couvreur
- Université Paris-Sud, Institut Galien, UMR 8612, Châtenay-Malabry, France-92296
| | - Didier Desmaele
- Université Paris-Sud, Institut Galien, UMR 8612, Châtenay-Malabry, France-92296
| | - Angelo Paci
- Université
Paris-Sud, Centre National de la Recherche
Scientifique (CNRS), and Gustave Roussy Cancer
Campus Grand Paris, Laboratoire de Vectorologie et Thérapeutiques Anticancéreuses, UMR 8203, Villejuif, France-94805
- Gustave Roussy Cancer Campus Grand Paris, Service Interdépartemental de Pharmacologie et d’Analyse du Médicament (SIPAM), Villejuif, France-94805
| |
Collapse
|
3
|
Choucha-Snouber L, Aninat C, Grsicom L, Madalinski G, Brochot C, Poleni PE, Razan F, Guillouzo CG, Legallais C, Corlu A, Leclerc E. Investigation of ifosfamide nephrotoxicity induced in a liver-kidney co-culture biochip. Biotechnol Bioeng 2012; 110:597-608. [PMID: 22887128 DOI: 10.1002/bit.24707] [Citation(s) in RCA: 84] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2012] [Revised: 08/01/2012] [Accepted: 08/02/2012] [Indexed: 11/06/2022]
Abstract
In this article, we present a liver-kidney co-culture model in a micro fluidic biochip. The liver was modeled using HepG2/C3a and HepaRG cell lines and the kidney using MDCK cell lines. To demonstrate the synergic interaction between both organs, we investigated the effect of ifosfamide, an anticancerous drug. Ifosfamide is a prodrug which is metabolized by the liver to isophosforamide mustard, an active metabolite. This metabolism process also leads to the formation of chloroacetaldehyde, a nephrotoxic metabolite and acrolein a urotoxic one. In the biochips of MDCK cultures, we did not detect any nephrotoxic effects after 72 h of 50 µM ifosfamide exposure. However, in the liver-kidney biochips, the same 72 h exposure leads to a nephrotoxicity illustrated by a reduction of the number of MDCK cells (up to 30% in the HepaRG-MDCK) when compared to untreated co-cultures or treated MDCK monocultures. The reduction of the MDCK cell number was not related to a modification of the cell cycle repartition in ifosfamide treated cases when compared to controls. The ifosfamide biotransformation into 3-dechloroethylifosfamide, an equimolar byproduct of the chloroacetaldehyde production, was detected by mass spectrometry at a rate of apparition of 0.3 ± 0.1 and 1.1 ± 0.3 pg/h/biochips in HepaRG monocultures and HepaRG-MDCK co-cultures respectively. Any metabolite was detected in HepG2/C3a cultures. Furthermore, the ifosfamide treatment in HepaRG-MDCK co-culture system triggered an increase in the intracellular calcium release in MDCK cells on contrary to the treatment on MDCK monocultures. As 3-dechloroethylifosfamide is not toxic, we have tested the effect of equimolar choloroacetaldehyde concentration onto the MDCK cells. At this concentration, we found a quite similar calcium perturbation and MDCK nephrotoxicity via a reduction of 30% of final cell numbers such as in the ifosfamide HepaRG-MDCK co-culture experiments. Our results suggest that ifosfamide nephrotoxicity in a liver-kidney micro fluidic co-culture model using HepaRG-MDCK cells is induced by the metabolism of ifosfamide into chloroacetaldehyde whereas this pathway is not functional in HepG2/C3a-MDCK model. This study demonstrates the interest in the development of systemic organ-organ interactions using micro fluidic biochips. It also illustrated their potential in future predictive toxicity model using in vitro models as alternative methods.
Collapse
Affiliation(s)
- Leila Choucha-Snouber
- CNRS UMR 7338, Laboratoire de Biomécanique et Bio Ingénierie, Université de Technologie de Compiègne, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Chen N, Hanly L, Rieder M, Yeger H, Koren G. The effect of N-acetylcysteine on the antitumor activity of ifosfamide. Can J Physiol Pharmacol 2011; 89:335-43. [PMID: 21609276 DOI: 10.1139/y11-028] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Ifosfamide-induced nephrotoxicity is a serious adverse effect in children undergoing chemotherapy. Our previous cell and rodent models have shown that the antioxidant N-acetylcysteine (NAC), used extensively as an antidote for acetaminophen poisoning, protects renal tubular cells from ifosfamide-induced nephrotoxicity at a clinically relevant concentration. For the use of NAC to be clinically relevant in preventing ifosfamide nephrotoxicity, we must ensure there is no effect of NAC on the antitumor activity of ifosfamide. Common pediatric tumors that are sensitive to ifosfamide, human neuroblastoma SK-N-BE(2) and rhabdomyosarcoma RD114-B cells, received either no pretreatment or pretreatment with 400 µmol/L of NAC, followed by concurrent treatment with NAC and either ifosfamide or the active agent ifosfamide mustard. Ifosfamide mustard significantly decreased the growth of both cancer cell lines in a dose-dependent manner (p < 0.001). The different combined treatments of NAC alone, sodium 2-mercaptoethanesulfonate alone, or NAC plus sodium 2-mercaptoethanesulfonate did not significantly interfere with the tumor cytotoxic effect of ifosfamide mustard. These observations suggest that NAC may improve the risk/benefit ratio of ifosfamide by decreasing ifosfamide-induced nephrotoxicity without interfering with its antitumor effect in cancer cells clinically treated with ifosfamide.
Collapse
Affiliation(s)
- Nancy Chen
- Department of Physiology and Pharmacology, The University of Western Ontario, London, Canada
| | | | | | | | | |
Collapse
|
5
|
Lu H, Wang JJ, Chan KK, Philip PA. Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6. Xenobiotica 2008; 36:367-85. [PMID: 16854777 DOI: 10.1080/00498250600598486] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
The aim was to identify the hepatic cytochromes P450 (CYPs) responsible for the enantioselective metabolism of ifosfamide (IFA). The 4-hydroxylation, N2- and N3-dechloroethylation of IFA enantiomers were monitored simultaneously in the same metabolic systems using GC/MS and pseudoracemate techniques. In human and rat liver microsomes, (R)-IFA was preferentially metabolized via 4-hydroxylation, whereas its antipode was biotransformed in favour of N-dechloroethylation. CYP3A4 was the major enzyme responsible for metabolism of IFA enantiomers in human liver. The study also revealed that CYP3A (human CYP3A4/5 and rat CYP3A1/2) and CYP2B (human CYP2B6 and rat CYP2B1/2) enantioselectively mediated the 4-hydroxylation, N2- and N3-dechloroethylation of IFA. CYP3A preferentially supported the formation of (R)-4-hydroxyIFA (HOIF), (R)-N2-dechloroethylIFA (N2D) and (R)-N3-dechloroethylIFA (N3D), whereas CYP2B preferentially mediated the generation of (S)-HOIF, (S)-N2D and (S)-N3D. The enantioselective metabolism of IFA by CYP3A4 and CYP2B1 was confirmed in cDNA transfected V79 cells.
Collapse
Affiliation(s)
- H Lu
- College of Pharmacy, Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA.
| | | | | | | |
Collapse
|
6
|
Abstract
The objective of this study was to study the enantiomer-enantiomer interaction of ifosfamide (IFA) in a rat model. Following intravenous administration of individual IFA enantiomers or pseudo-racemates to male Sprague-Dawley rats, two enantiomers and their metabolites, 4-hydroxyIF (HOIF), N2-dechloroethylIF (N2D), N3-dechloroethylIF (N3D), and isophosphoramide (IPM), were quantified using gas chromatography/mass spectrometry (GC/MS) and isotope dilution techniques. In addition, the mutual inhibition in the metabolism between two stereoisomers was also investigated in vitro using rat liver microsomes. Pharmacokinetic parameters were similar between (R)-IFA and (S)-IFA when individual enantiomers were intravenously administered to rats separately. However, in the rats administered with the IFA racemate, half-life, mean residence time (MRT), and area under the concentration-time curve (AUC) values of (S)-IFA were significantly increased with total body clearance (CLT) being decreased. No significant difference in volumes of distribution (Vss), and renal clearance (CLr) and blood cell partition was observed between two enantiomers regardless of (R)-IFA and (S)-IFA being administered separately or in combination as a racemate. The results from the in vitro metabolism and inhibition experiment suggested that each IFA enantiomer inhibited the metabolism of its antipode in a competitive manner. It is concluded that the enantiomeric interaction of IFA mainly occurred in the process of metabolism with (S)-IFA being affected to a larger extent.
Collapse
Affiliation(s)
- H Lu
- College of Pharmacy, The Ohio State University, Columbus, OH, USA.
| | | | | |
Collapse
|
7
|
Anderson P, Aguilera D, Pearson M, Woo S. Outpatient Chemotherapy plus Radiotherapy in Sarcomas: Improving Cancer Control with Radiosensitizing Agents. Cancer Control 2008; 15:38-46. [DOI: 10.1177/107327480801500105] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Background Cancer control by radiotherapy (RT) can be improved with concurrent chemotherapy. Outpatient strategies for sarcomas that combine chemotherapy and RT are possible since supportive care and RT techniques have improved. Methods The current status of non-anthracycline chemotherapy in combination with radiation for high-risk sarcoma is reviewed. Results Ifosfamide with mesna and newer activated ifosfamide agents (ZIO-201 and glufosfamide) have high potential to improve sarcoma cancer control. In Ewing's sarcoma and osteosarcoma, high-dose ifosfamide with mesna (2.8 g/m2/day of each x 5 days; mesna day 6) can be safely given to outpatients using continuous infusion. Reducing ifosfamide nephrotoxicity and central nervous system side effects are discussed. Other outpatient radiosensitization regimens include gemcitabine (600–1000 mg/m2/dose IV over 1 hour weekly x 2–3 doses), temozolomide (75 mg/m2/daily x 3–6 weeks), or temozolomide (100 mg/m2/dose daily x 5) + irinotecan (10 mg/m2/dose daily x 5 x 2 weeks). In osteosarcoma with osteoblastic metastases on bone scan, samarium (1 mCi/kg; day 3 of RT) and gemcitabine (600 mg/m2 IV over 1 hour day 9 of RT) is a radiosensitization strategy. Future drugs for radiosensitization include beta-D-glucose targeted activated ifosfamide (glufosfamide) and sapacitabine, an oral nucleoside with in vitro activity against solid tumors including sarcomas. Conclusions The potential to treat major causes of sarcoma treatment failure (local recurrence and distant metastases) with concurrent chemotherapy during radiation should be considered in high-grade sarcomas.
Collapse
Affiliation(s)
- Pete Anderson
- Departments of Pediatrics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
| | - Dolly Aguilera
- Departments of Pediatrics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
| | - Margaret Pearson
- Departments of Pediatrics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
| | - Shaio Woo
- Radiation Oncology at The University of Texas M. D. Anderson Cancer Center, Houston, Texas
| |
Collapse
|
8
|
Samel S, Keese M, Lux A, Jesnowski R, Prosst R, Saller R, Hafner M, Sturm J, Post S, Löhr M. Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide. Cancer Gene Ther 2006; 13:65-73. [PMID: 16096652 DOI: 10.1038/sj.cgt.7700849] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The prognosis of peritoneal spread from gastrointestinal cancer and subsequent malignant ascites is poor, and current medical treatments available are mostly ineffective. Targeted chemotherapy with intraperitoneal prodrug activation may be a beneficial new approach. L293 cells were genetically modified to express the cytochrome P450 enzyme 2B1 under the control of a cytomegalovirus immediate early promoter. This CYP2B1 enzyme converts ifosfamide to its active cytotoxic compounds. The cells are encapsulated in a cellulose sulfate formulation (Capcell). Adult Balb/c mice were inoculated intraperitoneally with 1 x 10(6) colon 26 cancer cells, previously transfected with GFP to emit a stable green fluorescence, by injection into the left lower abdominal quadrant. Two or five day's later animals were randomly subjected to either i.p. treatment with ifosfamide alone or ifosfamide combined with microencapsulated CYP2B1-expressing cells. Peritoneal tumor volume and tumor viability were assessed 10 days after tumor inoculation by means of fluorescence microscopy, spectroscopy and histology. Early i.p. treatment with ifosfamide and CYP2B1 cells resulted in a complete response. Treatment starting on day 5 and single-drug treatment with ifosfamide resulted in a partial response. These results suggest that targeted i.p. chemotherapy using a combination of a prodrug and its converting enzyme may be a successful treatment strategy for peritoneal spread from colorectal cancer.
Collapse
Affiliation(s)
- S Samel
- Department of Surgery, University Hospital Mannheim, University of Heidelberg, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Germann N, Urien S, Rodgers AH, Ratterree M, Struck RF, Waud WR, Serota DG, Bastian G, Jursic BS, Morgan LR. Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide. Cancer Chemother Pharmacol 2004; 55:143-51. [PMID: 15592722 DOI: 10.1007/s00280-004-0894-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2003] [Accepted: 06/24/2004] [Indexed: 10/26/2022]
Abstract
BACKGROUND Isophosphoramide mustard (IPM) is the cytotoxic alkylating metabolite of Ifosfamide (IFOS). IPM is being readied for a phase I clinical trial. In the present preclinical study, IPM was evaluated for usage in multidose intravenous (IV) infusion protocols. METHODS Mice and dogs received IV IPM daily for 3 days. Single-day dosing-oral and IV-to mice, rats, and monkeys is also reviewed for comparison. Complete toxicology studies were completed in the mice and dogs. For mice, dogs and monkeys, IV pharmacokinetic studies were conducted and compared. RESULTS For mice, the LD(10) for the 3-day IV schedule for IPM was calculated to be 119 mg/kg (with 95% confidence limits of 87-134 mg/kg) (combined sexes), and for adult male dogs the maximum tolerated dose (MTD) was 5 mg/kg. Pharmacokinetic studies in mice, dogs and monkeys were compared and projected to human dosing. For dogs that received 10 mg/kg of IPM, T(1/2beta) was 0.99 h, and clearance was constant (1.01 l/h/kg). IPM was detected from 0 h to 1.5 h after the 5 mg/kg dose and from 0 h to 2 h after the 10 mg/kg dose; none was detected after 2 h. The IV MTD in dogs was 5 mg/kg per day for 3 days. Renal tubular necrosis and bone marrow failure were the causes of death. Transient liver, renal and bone marrow toxicity and gastrointestinal dysfunction were seen at low doses (<5 mg/kg) in dogs. In mice (receiving 100 mg/kg IV) plasma concentrations disappeared in less than 1 h (T(1/2alpha) 2 min), with a clearance of 8.44 l/h/kg. For monkeys, the mean T(1/2) was 4.2 h. Median clearance was 1.65 l/h/kg and no IPM was detected 4 h after dosing. No potential IPM metabolites could be detected in any of the studies. In vitro, plasma protein bound 90% of IPM within 5 min of incubation. CONCLUSIONS Predictions for human pharmacokinetic parameters and dosing are made from allometric analysis using the above three species. Data predicted an acceptable starting dose of 30 mg/m(2) with a clearance of 39.5 l/h, and a T(1/2) of 1 h 45 min for a 70-kg patient.
Collapse
Affiliation(s)
- N Germann
- Service de pharmacology, Centre René Huguenin, 35 rue Dailly, 92210, Saint Cloud, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Larson RR, Khazaeli MB, Dillon HK. Development of an HPLC method for simultaneous analysis of five antineoplastic agents. APPLIED OCCUPATIONAL AND ENVIRONMENTAL HYGIENE 2003; 18:109-19. [PMID: 12519685 DOI: 10.1080/10473220301432] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Simultaneous analysis of common antineoplastic agents potentially hazardous to healthcare workers is of much interest for the evaluation of the overall health risk to these workers. Such analysis could be applied to both air and surface monitoring samples to provide a broader indication of risk to combinations of these agents. It was determined that the ability to simultaneously evaluate five frequently used, potentially hazardous agents was sufficient for general evaluation of exposures to healthcare workers. The approach used to select the five agents was to obtain a list of the agents used most frequently in both a cancer hospital and an outpatient cancer treatment center, then review the list to determine which agents were potentially more hazardous to human health. From these reviews, it was decided to attempt to develop an analytical method able to detect and quantify the presence of 5-fluorouracil, ifosfamide, cyclophosphamide, doxorubicin HCl, and paclitaxel. A reverse-phase high performance liquid chromatograph (HPLC) with a Waters Symmetry C8 column and a UV wavelength of 195 nm was selected for method development. The mobile phase was 22.75 percent acetonitrile in water buffered to a pH of 6.0. The HPLC analytical method developed is able to detect all five agents of interest, and at minimum detectable concentrations of 0.5-microgram/mL for each of the five agents.
Collapse
Affiliation(s)
- Rodney R Larson
- The University of Alabama at Birmingham School of Public Health, Birmingham, Alabama, USA
| | | | | |
Collapse
|
11
|
Baumann F, Preiss R. Cyclophosphamide and related anticancer drugs. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS 2001; 764:173-92. [PMID: 11817027 DOI: 10.1016/s0378-4347(01)00279-1] [Citation(s) in RCA: 77] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
This article presents an overview of the methods of bioanalysis of oxazaphosphorines, in particular, cyclophosphamide, ifosfamide, and trofosfamide as well as their metabolites. The metabolism of oxazaphosphorines is complex and leads to a large variety of metabolites and therefore the spectrum of methods used is relatively broad. The various methods used are shown in a table and the particularly important assays are described.
Collapse
Affiliation(s)
- F Baumann
- Institute of Clinical Pharmacology, University of Leipzig, Germany.
| | | |
Collapse
|
12
|
Breil S, Martino R, Gilard V, Malet-Martino M, Niemeyer U. Identification of new aqueous chemical degradation products of isophosphoramide mustard. J Pharm Biomed Anal 2001; 25:669-78. [PMID: 11377048 DOI: 10.1016/s0731-7085(00)00582-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
NMR (31P, 1H and 13C) spectroscopy was used to study the products of the degradation of isophosphoramide mustard (IPM) in buffered solutions at pH ranging from 1 to 13. At pH < or = 1, the only degradation compounds detected were phosphate ion (Pi) and chloroethylammonium chloride (CEA-HCl), resulting from the breakdown of the two P-N bonds (pathway Ia). At pH 9.3 and 13, only the products of 1,3-cyclization of the N-chloroethyl group (monoaziridinylIPM (monoAzIPM) and a very low level of bisaziridinylIPM (bisAzIPM)) were found after approximately 15 h of reaction (pathway II). At intermediate pH, the two pathways coexist. At pH 3.5 and 5.0, the P-N bond hydrolysis is the major pathway, but two final phosphorylated products were detected, Pi which represented 67% (pH 3.5) and 17% (pH 5.0) of all the IPM phosphorylated degradation products after approximately 15 h of reaction, and phosphorylethanolamine (PEA) which represented 16% (pH 3.5) and 46% (pH 5.0) of the same sum. PEA formation can be explained by the 1,5-cyclization of a transient compound giving a 1,3,2-oxazaphospholidine intermediate whose P-N bond is exclusively cleaved in acidic medium. The presence of monohydroxyIPM (monoOHIPM) (whose percentage increases with pH from 5% (pH 3.5) to approximately 28% (pH 5.0) of all the IPM phosphorylated degradation compounds), probably coming from the alkylation by water of an aziridine/aziridinium intermediate, demonstrates the occurrence of pathway II. At pH 7.0 and 7.4, the pathway II is initiated first, leading to 1,3-cyclization(s), followed by water alkylation of the aziridines formed. The sequences are IPM 1-->monoAzIPM 5-->bisAzIPM 9; IPM 1-->monoAzIPM 5-->monoOHIPM 6-->monoAzIPM with a N-hydroxyethylchain (presumed structure) 7-->dihydroxyIPM 8. Nevertheless, PEA and Pi are the final products observed, which implies the P-N bond hydrolysis of products 5-9 as demonstrated by the presence in the medium of CEA, aziridine and ethanolamine.
Collapse
Affiliation(s)
- S Breil
- Groupe de RMN Biomédicale, Laboratoire des IMRCP, Université Paul Sabatier, 118, route de Narbonne, 31062, Toulouse, France
| | | | | | | | | |
Collapse
|
13
|
Wang JJ, Lu H, Chan KK. Stereoselective pharmacokinetics of ifosfamide in male and female rats. AAPS PHARMSCI 2000; 2:E17. [PMID: 11741233 PMCID: PMC2751031 DOI: 10.1208/ps020217] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The stereoselective pharmacokinetics of ifosfamide (IF) were investigated in male and female Sprague-Dawley rats. Following intravenous administration of IF deuterium-labeled pseudoracemates into rats at 40 mg/kg, IF enantiomers and their metabolites, 4-hydroxyIF (HOIF), N2-dechloroethylIF (N2D), N3-dechloroethylIF (N3D), and isophosphoramide mustard (IPM) were quantitated in plasma and urine using gas chromatographic-mass spectrometry techniques with appropriately deuterium-labeled analogs as the internal standards. In addition, the intrinsic clearances of IF isomers in rat liver microsomes were estimated by the in vitro metabolism study. Following drug administration in male rats, (R)-IF exhibited a lower area under the curve value and a shorter half-life of 34.2 minutes than (S)-IF, which gave a half-life of 41.8 minutes. In female rats, the half-lives of (R)- and (S)-IF were found to be 62.1 and 75.1 minutes, respectively, significantly longer than those in male rats. No change in volume of distribution or renal clearance for IF enantiomers in all rats was observed, and the protein binding value was low, with no enantioselectivity. Both in vitro and in vivo studies showed that metabolism of (R)-IF proceeded in favor of the 4-hydroxylation pathway, whereas (S)-IF preferentially underwent N2- and N3-dechloroethylation. The observed stereoselectivity and gender difference in pharmacokinetics of IF in the rat are mainly attributed to its stereoselective metabolism.
Collapse
Affiliation(s)
- Jeff J. Wang
- School of Pharmacy, University of Southern California, Los Angeles, California USA
| | - Hong Lu
- School of Pharmacy, University of Southern California, Los Angeles, California USA
- Comprehensive Cancer Center, The Ohio State University, Room 308, 410 West 12th Avenue, 43210 Columbus, Ohio USA
| | - Kenneth K. Chan
- Colleges of Pharmacy and Medicine, The Ohio State University, Room 308, 410 West 12th Avenue, 43210 Columbus, Ohio USA
- Comprehensive Cancer Center, The Ohio State University, Room 308, 410 West 12th Avenue, 43210 Columbus, Ohio USA
| |
Collapse
|
14
|
Müller P, Jesnowski R, Karle P, Renz R, Saller R, Stein H, Püschel K, von Rombs K, Nizze H, Liebe S, Wagner T, Günzburg WH, Salmons B, Löhr M. Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors. Ann N Y Acad Sci 1999; 880:337-51. [PMID: 10415878 DOI: 10.1111/j.1749-6632.1999.tb09537.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The prognosis of pancreatic cancer is poor, and current medical treatment is mostly ineffective. The aim of this study was to design a new treatment modality in an animal model system. We describe here a novel treatment strategy employing a mouse model system for pancreatic carcinoma. Embryonal kidney epithelial cells were genetically modified to express the cytochrome P450 subenzyme 2B1 under the control of a cytomegalovirus (CMV) immediate early promoter. This CYP2B1 gene converts ifosfamide to its active cytotoxic compounds, phosphoramide mustard, which alkylates DNA, and acrolein, which alkylates proteins. The cells were then encapsulated in a cellulose sulphate formulation and implanted into preestablished tumors derived from a human pancreatic tumor cell line. Intraperitoneal administration of low-dose ifosfamide to tumor bearing mice that received the encapsulated cells results in partial or even complete tumor ablation. Such an in situ chemotherapy strategy utilizing genetically modified cells in an immunoprotected environment may prove useful for solid tumor therapy in man.
Collapse
Affiliation(s)
- P Müller
- Department of Medicine, University of Rostock, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Karle P, Müller P, Renz R, Jesnowski R, Saller R, von Rombs K, Nizze H, Liebe S, Günzburg WH, Salmons B, Löhr M. Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 1999; 451:97-106. [PMID: 10026857 DOI: 10.1007/978-1-4615-5357-1_16] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The prognosis of pancreatic adenocarcinoma is poor and current treatment is for the most part ineffective. We describe here a novel treatment strategy using a mouse model system for pancreatic cancer. Human embryonic epithelial cells have been genetically modified to express the cytochrome P450 2B1 enzyme under the control of a CMV immediate-early promoter. This CYP2B1 gene converts oxazaphosphorines (ifosfamide or cyclophosphamide) to their active cytotoxic compounds, phosphoramide mustard, which alkylates DNA, and acrolein, which alkylates proteins. A number of assays were performed to demonstrate the CYP2B1 gene function as well as toxic effects on neighbouring cells (bystander effect). The cells were then encapsulated in a cellulose sulphate formulation shown to be well tolerated in the pancreas of immunocompetent mice, and injected 1 cm away from pre-established tumours derived from a human pancreatic tumour cell line (PaCa-44). Intraperitoneal administration of low-dose ifosfamide to tumour bearing mice that received the encapsulated cells results in partial or even complete tumour ablation. Such an in situ chemotherapy strategy utilizing genetically modified cells in an immunoprotected environment may prove useful for solid tumour therapy in man.
Collapse
Affiliation(s)
- P Karle
- Institute of Virology, University of Veterinary Sciences, Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Springer JB, Colvin ME, Colvin OM, Ludeman SM. Isophosphoramide Mustard and Its Mechanism of Bisalkylation. J Org Chem 1998; 63:7218-7222. [PMID: 11672363 DOI: 10.1021/jo980546s] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
To investigate the mechanism(s) of bisalkylation by isophosphoramide mustard (IPM), IPM-beta,beta,beta',beta'-d(4) was synthesized and the products of its reaction with thiosulfate (at pD 7.0) were analyzed by NMR. By both (1)H and (13)C NMR, the distribution of deuterium in the products was consistent with bisalkylation through sequential aziridinyl intermediates [(NCH(2)CD(2)S):(NCD(2)CH(2)S) = 53:47]. Under the given reaction conditions, label scrambling as a result of thiosulfate acting as a leaving group was ruled out through control experiments. The data gave a calculated kinetic isotope effect of 0.97 per deuterium. For the initial aziridine species formed from IPM, ab initio quantum chemical calculations gave a hybridization value of sp(2.4)(-)(2.5) for each of the C-H bonds of the reaction centers, and this correlated with the observed inverse isotope effect. Other structure and bond order data were also determined for this aziridine intermediate and related compounds.
Collapse
Affiliation(s)
- James B. Springer
- Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, and Biology and Biotechnology Research Program, Lawrence Livermore National Laboratory, Livermore, California 94550
| | | | | | | |
Collapse
|
17
|
|
18
|
Wang JJ, Chan KK. Analysis of ifosfamide, 4-hydroxyifosfamide, N2-dechloroethylifosfamide, N3-dechloroethylifosfamide and iphosphoramide mustard in plasma by gas chromatography-mass spectrometry. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL APPLICATIONS 1995; 674:205-17. [PMID: 8788150 DOI: 10.1016/0378-4347(95)00309-6] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
A sensitive and specific method for the simultaneous quantitation of ifosfamide (IF), 4-hydroxylifosfamide (4-OHIF), N2-dechloroethylifosfamide (N2D), N3-dechloroethylifosfamide (N3D) and iphosphoramide mustard (IPM) has been developed using gas chromatography-mass spectrometry (GC-MS) with an ion-trap mass spectrometer. Deuterium labeled analogues for each of these analytes were synthesized as the internal standards. The labile 4-OHIF in plasma was first converted to the more stable cyanohydrin adducts before dichloromethane extraction. IPM was extracted by C18 reversed-phase resin. All analytes were converted to their silyl derivatives before GC-MS analysis. The sensitivity limits ranged from 0.1 to 0.5 microgram/ml when 100 microliters of plasma was used. This method was validated with within-run coefficients of variation less than 5% (n = 8) and between-run coefficients of variation less than 12% (n = 6). The method was applied to the determination of plasma levels of IF and metabolites in the rat.
Collapse
Affiliation(s)
- J J Wang
- School of Pharmacy, University of Southern California, Los Angeles 90033, USA
| | | |
Collapse
|
19
|
Boddy AV, Proctor M, Simmonds D, Lind MJ, Idle JR. Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. Eur J Cancer 1995; 31A:69-76. [PMID: 7695982 DOI: 10.1016/0959-8049(94)00300-t] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Ifosfamide (IFO) at a dose of 5 g/m2, was administered as a 24-h infusion to 15 patients with metastatic (12) or locally advanced (3) breast cancer (age range 33-59 years, median 46). Concurrent chemotherapy was doxorubicin (40 mg/m2) or epirubicin (60 mg/m2). Ifosfamide and its metabolites were measured in plasma and urine during and for 24 h after the infusion using a high performance thin layer chromatography (HPTLC) technique. Patients' haematological toxicity and biochemistry were monitored during treatment and patients were followed for up to 2 years after therapy. At the time of evaluation, 5 of the patients were alive, 2 of whom had not relapsed. A marked variation was observed in the pharmacokinetics and metabolism of ifosfamide in the evaluable patients. Clearance, volume of distribution and half-life of the drug were 3.48 +/- 0.88 1/h/m2, 0.56 +/- 0.22 l/kg and 4.68 +/- 2.01 h, respectively. There was no apparent correlation between these pharmacokinetic variables and patient age, weight or renal function. AUCs of the ultimate alkylating species isophosphoramide mustard (IPM) varied over 6-fold, as did those of the inactivated metabolite carboxyifosfamide (CX). AUCs of dechloroethylated metabolites varied 4-fold (3-dechloroethylifosfamide, 3-DCI) or 8-fold (2-DCI), while that of the parent compound varied only 2.5-fold. Variation in recovery of the metabolites in urine varied over an even wider range, total recovery varying from 17.5 to 81.8% of the dose administered. There was little apparent correlation between pharmacokinetic and metabolite parameters of IFO and haematological toxicity. However, there was a marked negative correlation between both progression-free interval and survival and the AUCs of the products of IFO activation (IPM and CX). In addition, the recovery of IPM in urine was higher in patients experiencing a partial response compared to those with progressive or stable disease. Recovery of dechloroethylated metabolites correlated positively with survival, if 1 poor prognosis patient was excluded. Although far from conclusive, these results give some insight into a possible mechanism of action of ifosfamide and indicate that some species other than IPM, as measured systemically, is responsible for the pharmacological effects of this drug.
Collapse
Affiliation(s)
- A V Boddy
- Cancer Research Unit, Medical School, University of Newcastle upon Tyne, U.K
| | | | | | | | | |
Collapse
|